CME/CE Accreditation Information Return to Previous

Targeting Mealtime Glucose Excursions and Glycemic Control in T2DM: How and When Should We Use Newer Insulins?

There is a clear need to educate clinicians who manage patients with T2DM, particularly those in underserved communities, about faster-acting mealtime insulins, including how to identify eligible patients, and how to implement individualized treatment protocols and address challenges related to insulin initiation and intensification. In addition, it is essential that multidisciplinary HCPs are updated regarding practical strategies for implementing effective telehealth protocols to improve the ability of all patients with diabetes to self-manage their disease and remain actively engaged in care.

In this activity, participants will be guided through a series of small group learning modules by a group leader who is a well-recognized T2DM expert within their community. The curriculum focuses on a group’s collective accomplishment of a shared goal — improving outcomes for patients with T2DM who are likely to benefit from the addition of a newer insulin, such as an MTI, to their therapeutic regimen and improving the delivery of telehealth services to underserved patients with T2DM via a multidisciplinary team approach.

Primary Care/General Practitioner physicians (MDs/DOs), NPs, PAs, and Certified Diabetes Educators (CDEs)

This activity is supported by an educational grant from Lilly. 

After taking part in this educational activity, clinicians should be better able to:

  • Utilize validated, evidence-based measurement tools beyond A1c to identify patients with T2DM who could benefit from the addition of a rapid-acting mealtime insulin (MTI) to their current treatment regimen
  • Identify and address factors that contribute to delays in treatment intensification, including the documented underuse of newer insulins, among patients with T2DM
  • Implement individualized treatment strategies that incorporate the use of newer insulins, including rapid-acting MTIs, for appropriate patients with T2DM
  • Utilize the full diabetes care team, with a focus on the use of telehealth services, to educate and support patients with T2DM who are either prescribed or may be candidates for newer insulin formulations

Accredited by Haymarket Medical Education.

In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



IPCE credit

This activity was planned by and for the healthcare team, and learners will receive 3.5 Interprofessional Continuing Education (IPCE) credit for learning and change.


AMA PRA Category 1 CreditsTM

Haymarket Medical Education designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ANCC Contact Hours

This activity is awarded 3.5 contact hours (based on 60 minutes per contact hour).

Haymarket Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

This IPCE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this IPCE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and Lilly. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact


John E. Anderson, MD
Internal Medicine and Diabetes
The Frist Clinic
Nashville, TN

Dr. Anderson has reported the following relevant financial relationships:
Speaker: Bayer, Eli Lilly & Company, Novo Nordisk, Inc. Sanofi
Consultant: Abbott Diabetes, Alfasigma USA, Inc., AstraZeneca Pharmaceuticals, Bayer, Boehringer Ingelheim, Eli Lilly & Company, Intuity Medical, Inc., Novo Nordisk, Inc., Sanofi

Wendy Lane, MD
Clinical Endocrinologist
Mountain Diabetes and Endocrine Center
Asheville, NC

Dr. Lane has reported the following relevant financial relationships:
Speaker: DexCom, Inc., Novo Nordisk, Inc.
Consultant: Arecor, Novo Nordisk, Inc.
Investigator: Abbott, Lexicon Pharmaceuticals, Inc., Novo Nordisk, Inc.
All of the relevant financial relationships listed for these individuals have been mitigated.

None of the planners, reviewers, and Haymarket Medical Education staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.  

To obtain credit, a score of 70% or better on the post-assessment is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.